Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 1
EGFR mNSCLC: Treatment Overview and Challenges
Panelists discuss how EGFR tyrosine kinase inhibitors (TKIs) have revolutionized first-line treatment for EGFR-positive non–small cell lung cancer (NSCLC).
Video Player is loading.
Video content above is prompted by the following:
- Provide a brief overview of the treatment landscape of first-line treatment for patients with EGFR-positive NSCLC.